Menu Search
Equities

SNDL Inc

SNDL:NAQ

SNDL Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.10
  • Today's Change-0.03 / -1.41%
  • Shares traded4.58k
  • 1 Year change+7.14%
  • Beta3.1833
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year SNDL Inc grew revenues 27.63% from 712.20m to 909.01m while net income improved from a loss of 335.11m to a smaller loss of 172.66m.
Gross margin25.04%
Net profit margin-12.82%
Operating margin-13.15%
Return on assets-7.67%
Return on equity-8.90%
Return on investment-8.32%
More ▼

Cash flow in CADView more

In 2023, cash reserves at SNDL Inc fell by 84.55m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 16.65m. In addition the company used 24.82m on investing activities and also paid 43.08m in financing cash flows.
Cash flow per share-0.1579
Price/Cash flow per share--
Book value per share3.43
Tangible book value per share2.87
More ▼

Balance sheet in CADView more

SNDL Inc has a Debt to Total Capital ratio of 11.25%, a higher figure than the previous year's 10.41%.
Current ratio4.34
Quick ratio2.98
Total debt/total equity0.1284
Total debt/total capital0.1125
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.